Envoy Medical, Inc. (COCH): Nasdaq/NYSE listing notice — Envoy Medical receives Nasdaq deficiency notice for minimum bid price non-compliance

Envoy Medical, Inc.

Nasdaq notified Envoy Medical on Nov 19, 2025 that common stock failed minimum $1.00 bid price for 30 consecutive business days.
Company has 180 days, until May 18, 2026, to regain compliance by closing at $1.00+ for 10 consecutive business days.
If not cured, Envoy may seek a second 180-day period by meeting other listing standards and considering a reverse stock split.
Delisting would occur if compliance not achieved; company may appeal to a Nasdaq Hearings Panel.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Envoy Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

November 19, 2025, Envoy Medical, Inc. (the “Company”) received a staff determination notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), informing the Company that its Class A Common Stock, par value $0.0001 per share (the "Common Stock"), has failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing of the Common Stock on The Nasda

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Envoy Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-114725

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.